Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease (Kawasaki)

August 18, 2017 updated by: Hospices Civils de Lyon

Kawasaki disease (KD) is an acute systemic vasculitic syndrome with coronary tropism.

It has been reported worldwide, but it is ten times more common in Asian population. The annual incidence in children under 5 years in Europe is estimated at 8 to 100000. It is the second vasculitis of the child by its frequency after rheumatoid purpura. It occurs in 80% of cases between 1 and 5 years, with a maximal incidence around the age of 12 months.

It may results in acquired heart disease in children in developed countries, and may be the cause of premature coronary artery disease in adulthood.

A polymorphism was recently associated with the occurrence of disease in a Japanese and U.S population. (C allele of SNP itpkc_3, with a risk multiplied by 2). However, data are conflicting on this issue and the prevalence of this allel is unknown in North America and Europe populations.

The clinical picture of KD associate a persistent fever and an antipyretics resistance with mucocutaneous signs and bulky cervical lymphadenopathy usually unilateral. Diagnosis is confirmed by the presence of five clinical signs (major criteria). The presence of inconsistent coronary lesions in cardiac ultrasound can confirm the diagnosis.

KD can resolve spontaneously with no treatment. The severity of the disease is primarily related to complications of coronary aneurysms in acute or chronic stages.

Several arguments support the fact that adult patients have diffuse vascular lesions different from aneurysmal lesions initially described in childhood.

Despite abundance of publications on KD, there is no prospective or retrospective study which explored anomalies resulting from KD in adult subjects.

Therefore, this project will describe the patient's vascular evolution, the prevalence of atherosclerotic lesions and to determine the biological and functional abnormalities, markers of accelerated atherosclerosis.

Hypothesis : A history of Kawasaki disease represents a cardiovascular risk factor in adulthood.

The main objective is to evaluate the prevalence of atherosclerotic lesions, their extent and their severity in adults with a history of KD in childhood compared to a control population.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

43

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron, France, 69677
        • Hôpital Cardiologique Louis Pradel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • History of KD before the age of 18, with or without macroscopic coronary lesions in the childhood phase. (KD group only)
  • 18 years old or older at the time of the study.
  • Agree on participating to all explorations of the study.
  • Accept genotyping.
  • Absence of cardiovascular risk factors

Exclusion Criteria:

  • Atypical KD (KD group only)
  • Documented or suspected coronary ischemia,
  • Refusal to participate to the study or sign the consent
  • Contra-indication to the injection of iodinated contrast agents (allergy, renal failure)
  • Hypersensitivity to dobutamine,
  • No effective contraception method for females with child bearing potential,
  • Breastfeeding, or pregnant females,
  • Treatment modifying endothelial reactivity
  • History of severe intolerance to iodinated contrast agents,
  • Subjects who can't hold their breath for at least 20 seconds,
  • Irregular or absence of sinus rhythm, especially atrial or ventricular arrhythmia
  • Unability to give information to the subject,
  • No coverage from a Social Security system
  • Deprivation of civil rights

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patients KD
Adults with a history of KD disease in childhood

complete cardiac evaluation with :

Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping

Other: Case Control
Control group, healthy volunteers matched for age and sex with the KD group

complete cardiac evaluation with :

Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of carotid and coronary atherosclerotic plaques at vascular Doppler ultrasound and coronary scan in the KD population versus control population
Time Frame: 1 day
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Early markers of atherosclerosis
Time Frame: 1 day

Secondary Outcomes consist of early markers of atherosclerosis:

  • Carotid intima-media thickness
  • Endothelial dysfunction of coronary arteries,
  • Myocardial blood flow at rest and under pharmacological stress (adenosine)
  • Myocardial systolic function overall and segmental at rest and under pharmacological stress (dobutamine)
  • Early biological markers of atherosclerosis.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sylvie Di Filippo, Pr, Hospices Civiles de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2011

Primary Completion (Actual)

April 13, 2015

Study Completion (Actual)

April 13, 2015

Study Registration Dates

First Submitted

September 21, 2011

First Submitted That Met QC Criteria

September 22, 2011

First Posted (Estimate)

September 26, 2011

Study Record Updates

Last Update Posted (Actual)

August 22, 2017

Last Update Submitted That Met QC Criteria

August 18, 2017

Last Verified

August 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kawasaki Disease

Clinical Trials on Cardiac evaluation

3
Subscribe